Previous studies have shown that Zhichan powder elevated immunity and suppressed oxidation in mice. Rat models of Parkinson's disease were induced by stereotaxically injecting 6-hydroxydopamine into the substantia nigra. The rat models were intragastrically treated with Zhichan powder, which is composed of milkvetch root, ginseng, bunge swallowwort root, himalayan teasel root, Magnolia officinalis, Ligustrum lucidum Ait. and szechwan lovage rhizome. Immunohistochemistry and reverse transcription-PCR results demonstrated that mRNA and protein expression of tumor necrosis factor receptor 1, Fas, caspase-8, cytochrome C, Bax, caspase-3, and p53 significantly increased, but Bcl-2 expression significantly decreased in the substantia nigra of rats with Parkinson's disease. Following Zhichan powder administration, mRNA and protein expression of tumor necrosis factor receptor 1, Fas, caspase-8, cytochrome C, Bax, caspase-3, and p53 diminished, but Bcl-2 expression increased in the rat substantia nigra. These results indicate that Zhichan powder regulates signal transduction protein expression, inhibits apoptosis, and exerts therapeutic effects on Parkinson's disease.
INTRODUCTION
The precise etiopathology and pathogenesis of Parkinson's disease remain unclear and are probably associated with heredity, environmental factors, excitatory toxins, excessive oxidative stress, the aging nervous system and signal transduction-associated gene expression [1] . Levodopa substitution therapy has been considered an effective method to treat Parkinson's disease [2] , but this therapy can only improve patients' clinical symptoms, and cannot affect the Parkinson's disease process. Moreover, it is difficult to increase the therapeutic efficacy of levodopa and there are unpleasant side effects [3] . Many medicines are used to treat Parkinson's disease in China, such as the anti-oxidative stress drugs triptolide, fucoidan, ligustrazine and the anti-apoptosis drugs resveratrol, ginsenoside Rg1 and Rg2, daidzein and manyprickle acanthopanax root. The above-described medicines exert their effects by regulating the status of the whole body. These medicines are quite mild, do not have side effects, and can be used for a long period [4] [5] [6] . They are medicinal herbs, decoctions or monomers that were developed by clinical experience or as ancient Chinese herbal formulas. However, the drugs developed with specific anti-Parkinson's disease mechanisms of action are few, especially proprietary Chinese medicines Zhichan powder is composed of milkvetch root, ginseng, bunge swallowwort root, himalayan teasel root, Magnolia officinalis, Ligustrum lucidum ait and szechwan lovage rhizome. Crude milkvetch root tastes sweet, with a warming effect, and can increase energy and promote blood circulation and generation. Ginseng tastes sweet, is mildly bitter, strengthens qi and confers resistance to senility [7] . Bunge swallowwort root is dry, bitter, and acerbic, and nourishes the blood, tonifies the liver, and invigorates qi and blood [7] .
A previous study confirmed that Zhichan powder elevated the immunity of Parkinson's disease mice, decreased the production of monoamine oxidase-B, and contributed to the secretion of superoxide dismutase [8] . The present study analyzed the effects of Zhichan powder on signal transduction and apoptosis-associated protein expression, explored the protective mechanism of Zhichan powder on dopaminergic neurons in the substantia nigra of Parkinson's disease rats, and provided theoretical evidence for the use of traditional Chinese medicine in the treatment of Parkinson's disease.
RESULTS

Quantitative analysis of experimental animals
Out of 90 Sprague-Dawley rats used in this study, 70 were randomly selected to undergo induction of a model of Parkinson's disease. Establishment of the model was successful in 42 rats (a success rate of 60%). The remaining 20 rats served as controls. A total of 42 Parkinson's model rats were randomly assigned to the model group (n = 20), the 7-week Zhichan powder group (n = 11) and the 14-week Zhichan powder group (n = 11). Rats in the 7-and 14-week tremor-stopping powder groups were administered 2 g/kg Zhichan powder intragastrically. Rats in the control and model groups were administered 2 mL/100 g saline. Three rats in the control group, eight in the model group, four in the 7-week Zhichan powder and four in the 14-week Zhichan powder group died during model induction and the rest of the study. After anatomical analysis, it was determined that 12 rats succumbed to esophageal mucosa injury and gastric bleeding and three rats died from emaciation (difficulty in taking food). A total of 17 rats in the control group, 12 in the model group, 7 in the 7-week Zhichan powder group and 7 in the 14-week Zhichan powder group were included in the final analysis. Reverse transcription-PCR results showed that caspase-3, Bax and p53 mRNA expression was significantly higher, but Bcl-2 mRNA expression was lower in the model group compared to the control group (P < 0.01). Caspase-3, Bax and p53 mRNA expression was significantly lower, but Bcl-2 mRNA expression was greater following Zhichan powder treatment (P < 0.01). TNFR1, Fas, caspase-8 and cytochrome C mRNA expression was significantly greater in the model group than in the control group (P < 0.01). However, TNFR1, Fas, caspase-8 and cytochrome C mRNA expression was significantly decreased following Zhichan powder treatment (P < 0.01), especially after 14 weeks of Zhichan powder treatment (P < 0.01; Figure 3 , Table 1 ).
DISCUSSION
Fas-induced apoptosis is mediated by various signaling pathways. FasL is predominantly expressed in activated natural killer cells, and interacts with Fas (CD95), resulting in target cell apoptosis [9] . Previous studies have found that caspase-3 [10] , caspase-8 [11] and Fas [12] [13] [14] siRNAs effectively inhibit apoptosis. TNF plays an important role in inducing apoptosis. TNF combined with TNFR1 leads to a large increase in TNFR1-associated death domain protein, which simultaneously participates in the activation of two pathways [15] : one is proapoptotic pathway mediated by Fas associated death domain protein, another is antiapoptotic pathway mediated by TNFR1 correlation factor.
Results from this study showed that Fas and TNFR1 expression was greater in the substantia nigra of rats with Parkinson's disease induced by 6-hydroxydopamine injection compared to controls. M: DL2000 DNA Marker. Caspase-3, Bax, p53, TNFR1, Fas, caspase-8 and cytochrome C mRNA expression were significantly greater, but Bcl-2 mRNA expression was lower in the model group compared with the control group. However, caspase-3, Bax, p53, TNFR1, Fas, caspase-8 and cytochrome C mRNA expression were decreased, but Bcl-2 mRNA expression was increased following Zhichan powder treatment, especially following 14 weeks of Zhichan powder treatment.
This indicates that Fas and TNFR1-mediated apoptosis signals were received by the cells, induced the upregulation of apoptosis-associated gene expression, promoted dopaminergic cell apoptosis, and resulted in the occurrence of Parkinson's disease in rats.
Immunohistochemical [16] . The Bax protein plays an important role in apoptosis in the substantia nigra, and its increase can upregulate the apoptosis of dopaminergic neurons [17] .
The Bcl-2 and Bax genes are a pair of apoptosis-regulated genes [18] . Bcl-2 blocks the release of cytochrome C, inhibits caspase-3 activation, and effectively suppresses the occurrence of apoptosis . Bax is a pro-apoptotic factor that promotes the release of cytochrome C [19] [20] [21] . In our study, apoptosis was further confirmed by caspase-3 activation [22] . Overexpression of Bcl-2 can cause changes in redox equilibrium in the nucleus and decrease caspase-3 activity [23] . Bcl-2, a substrate of caspase-3, can be hydrolyzed by caspase-3 [24] . Bcl-2 expression was reduced, but Bax expression was remarkably increased in the substantia nigra of Parkinson's disease rats, which suggested that Bcl-2 and Bax participated in an apoptosis-inducing effect. Following Zhichan powder treatment, Bax expression decreased, but Bcl-2 expression increased, suggesting that Zhichan powder suppressed Bax expression in the rat substantia nigra and inhibited neuronal apoptosis. These results also verified that the relative ratio of pro-apoptotic and anti-apoptotic proteins exerts an important effect in apoptosis. Bcl-2 forms a heterodimer with Bax to terminate apoptosis, but Bax/Bax homodimer formation can promote apoptosis, consistent with previously published results [25] [26] .
The p53 content was low in normal cells, but high in injured cells. The increased p53 levels led to an increased Bax/Bcl-2 ratio, resulting in apoptosis. The p53 gene indirectly regulates cytochrome C expression, and promotes apoptosis [25] [26] [27] . P53 expression in the model group was persistently increased, which indicated that excessive p53 activation probably participates in the pathological process of Parkinson's disease. Nevertheless, p53 expression was significantly reduced in the rat substantia nigra following 7 weeks of Zhichan powder treatment. P53 target gene expression was downregulated following 7 weeks of Zhichan powder treatment, and still downregulated at 14 weeks. This indicated that cytochrome C release caused the secretion of apoptotic factors and contributed to apoptosis following mitochondrial injury. Our results show that, Zhichan powder suppresses p53 and cytochrome C expression, enhances the tolerance of dopaminergic neurons to 6-hydroxydopamine, and promotes the recovery of neurological function. In summary, Zhichan powder inhibits signal transduction and apoptosis in the brain of Parkinson's disease rats. This provides novel theoretical evidence for clinical treatment and prevention of Parkinson's disease using Zhichan powder.
MATERIALS AND METHODS
Design
A randomized controlled animal study. [28] .
Time and setting
Drugs
Zhichan powder was prepared by Professor Guozhong Gai from Changchun University of Chinese Medicine, and composed of milkvetch root, ginseng, bunge swallowwort root, himalayan teasel root, Magnolia officinalis, Ligustrum lucidum ait and szechwan lovage rhizome (provided by the Pharmacy of Changchun University of Chinese Medicine). The above-mentioned drugs were crushed separately, mixed in a certain proportion, steeped in boiling water overnight, and decocted three times with water. The decoctions were merged and filtered. The filtrate was dried at 60-80°C. After trituration, a brown powder was obtained, and 1 g powder was equal to 5.36 g crude drug.
Methods
Preparation of 6-hydroxydopamine-induced Parkinson's disease models
The rats were anesthetized and placed on a stereotaxic apparatus (Ruiwode Life Science Co., Ltd., Shenzhen, Guangdong Province, China). The coordinates of the substantia nigra were identified [29] [30] : 1.1 mm lateral to the median line, 4.4 mm posterior to the anterior fontanelle, 7.5 mm below the dura mater. After injection of 6-hydroxydopamine (Sigma, St. Louis, MO, USA) 12 μg at 10 μL/min, the needle was maintained in place for 1-5 minutes. Anti-infective therapy was conducted for 5 days [31] [32] [33] . Two weeks later, 0.25 mg/kg apomorphine (Shenyang First Pharmacy Co., Ltd., Northeast Pharmaceutical Group, Shenyang, Liaoning Province, China) was subcutaneously injected into the rats. The times and direction of rotation within 40 minutes were recorded, once a week, for 6 consecutive weeks. The mean value of three consecutive sessions was used as the rotation time. An average velocity > 7 rotations/min was considered a successful model induction.
Intragastric administration of Zhichan powder
The rats in the 7-week and 14-week Zhichan powder groups were administered 2 g/kg Zhichan powder (200 mg/mL) intragastrically twice for 7 and 14 weeks. The rats in the control and model groups were daily given 2 mL/100 g saline intragastrically for 14 weeks.
Sample collection
After gavage, the rats were anesthetized for blood collection from the abdominal aorta, and then sacrificed. The substantia nigra was obtained from the brain on a super clean bench. One half was fixed in 10% formalin, and another half was stored at -80°C for further use.
Expression of TNFR1, Fas, caspase-8, cytochrome C, Bcl-2, Bax, caspase-3 and p53 in the rat substantia nigra, determined by immunohistochemical staining The rat substanitia nigra fixed in 10% formalin was embedded in paraffin and sectioned into 2-mm thick slices. These sections were subjected to immunohistochemical staining with streptavidin and peroxidase. Antigens were retrieved at 60°C for 120 minutes. These sections were deparaffinized, hydrated and immersed three times in PBS, each for 2 minutes.
The sections were incubated in 3% H 2 O 2 (Beijing Zhongnuo Taian Technology Co., Ltd., Beijing, China) for 10 minutes at room temperature to eliminate the activity of endogenous peroxidase, washed in PBS, blocked in 5% normal goat serum (Xinran Biotechnology, Shanghai, China) for 10 minutes at room temperature. After removal of serum, the sections were incubated with rabbit anti-TNFR1, Fas, caspase-8, cytochrome C, Bcl-2, Bax, caspase-3 or p53 polyclonal antibody (1: 50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4°C overnight. The sections were incubated in biotin-labeled goat anti-rabbit secondary antibody (Beijing Biosynthesis Biotechnology, Beijing, China) 1:500 in PBS at 37°C for 30 minutes, and then in horseradish peroxidase-conjugated streptavidin (Beijing Biosynthesis Biotechnology) 1:1 000 at 37°C for 30 minutes. A PBS wash was performed between each step. The sections were developed with 3, 3'-diaminobenzidine (Beijing Bole Life Science, Beijing, China), counterstained, dehydrated, permeabilized, mounted with Citifluor (Citifluor Ltd., London, United Kingdom), observed under a light microscope (Nikon, Tokyo, Japan), and photographed.
Caspase-3, Bax, Bcl-2, p53, TNFR1, Fas, caspase-8 and cytochrome C mRNA expression in the rat substantia nigra, measured by reverse transcription-PCR Total RNA was extracted with a Trizol kit (USA Life Technologics, Shanghai, China). PCR primers were synthesized by Shanghai Bioengineering Co., China. In accordance with the instructions of a GenAmpRNAPCR kit (Bioer Technology Co., Ltd., Hangzhou, China), the total reaction volume was 20 μL in a mixture containing 1 μL total RNA, 4 μL 5 × PCR buffer, 2 μL dNTPs (10 mM), 1.0 μL RNase inhibitor, 1 μL OligodT, 1 μL AMV reverse transcriptase and 10 μL sterile double distilled water. Following centrifugation, the reaction tube was incubated in a water bath at 37°C for 10 minutes, at 42°C for 1 hour, at 94°C for 5 minutes, and then cooled in an ice bath for 1 minute. The cDNA products were stored at -20°C. In accordance with the instructions of a GenAmpRNAPCR kit, 5 μL 10 × Taq enzyme buffer, 2 μL dNTPs (10 mM), 10 μL upstream target gene primer, 10 μL downstream target gene primer, 5 μL upstream internal reference primer, 5 μL downstream internal reference primer, 5 μL cDNA, 3 μL Taq enzyme, 5 μL diethyl pyrocarbonate-treated water were added in each 0.2 mL PCR reaction tube, for a total reaction volume of 50 μL. PCR primer sequences are listed in Table 2 . PCR reaction conditions are shown in Table 3 .
Using tris-acetate-ethylenediamine tetraacetic acid buffer, the samples were electrophoresed in 1.5% agarose (Japan Takara, Dalian, China) containing ethidium bromide (1 μg/μL final concentration) (Sangon, Shanghai, China) at 100 V for 25 minutes at room temperature. The gels were observed with a gel imaging system (Tianneng Biological Science Co., Ltd., Hangzhou, China), photographed, and the absorbance value was recorded. The expression of the target gene is shown as the absorbance ratio of target gene/β-actin.
Statistical analysis
The data were expressed as mean ± SD, and analyzed using SPSS 17.0 (SPSS, Chicago, IL, USA). One-way analysis of variance was used to compare the differences among groups. There were significant differences. A paired q-test was used to compare the difference between indices. TNFR1: Tumor necrosis factor receptor 1.
TNFR1: Tumor necrosis factor receptor 1.
